Maria L. Padilla, MD, Steven A. Sahn, MD and Charlie Strange, MD discuss the following:

  • Which CTDs should be included in a differential diagnosis of progressive dyspnea and restrictive lung disease?
  • What are the important serologic markers and when can they appear?
  • Are IPF and CTD mutually exclusive or can they be comorbidities?

Upon completion of the activity, participants should be able to:

  • Utilize indicators of disease status to diagnose, assess, and manage patients with IPF

Upon completion of the activity, participants should be able to:

  • Utilize indicators of disease status to diagnose, assess, and manage patients with IPF

Upon completion of the activity, participants should be able to:

  • Utilize indicators of disease status to diagnose, assess, and manage patients with IPF

Access other Therapeutic Areas: